Common PD-L1 inhibitors such as pembrolizumab can bind to PD-L1 on tumor cells, which prevents PD-L1 from binding to PD-1 on T cells and subsequently halting T cell inhibition, which enables T cells to exert a killing effect on cancer cells (Fig. 3). This evidence concerns the gene PDCD1 and neoplasm.